Sunitinib malate (Sutent) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours

For the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression is the therapeutic value of sunitinib comparable with that of everolimus.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.